[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)]
[Notices]
[Pages 16405-16406]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06546]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Patent License: Development and 
Commercialization of Peptides Promoting Lipid Efflux for the Treatment 
of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Heart, Lung, and Blood Institute (NHLBI), an 
institute of the National Institutes of Health; an agency within the 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to commercialize the invention(s) embodied 
in the intellectual property estate stated in the Summary Information 
section of this notice to Corvidia Therapeutics Inc. (Corvidia) located 
in Waltham, MA and incorporated under the laws of Delaware.

DATES: Only written comments and/or applications for a license which 
are received by the NHLBI Office of Technology Transfer and Development 
on or before April 19, 2017 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated exclusive license should be 
directed to: Cristina Thalhammer-Reyero, Ph.D., MBA, Senior Licensing 
and Patenting Manager, NHLBI Office of Technology Transfer and 
Development, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-
2479; Telephone: +1-301-435-4507; Fax: +1-301-594-3080; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: The following represents the intellectual 
property to be licensed under the prospective agreement:
    U.S. Provisional Patent Application Serial No. 61/045,213, filed 
04/15/2008; PCT Application No. PCT/US2009/040560, filed 04/14/2009; 
U.S. Patent Application Serial No.12/937,974, issued as 8,936,787 on 
01/20/2015; Titled ``Peptides Promoting Lipid Efflux'' (NIH Reference 
No. E-138-2008/0).
    With respect to persons who have an obligation to assign their 
right, title and interest to the Government of the United States of 
America, the patent rights in these inventions have been assigned to 
the Government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to: ``Treatment of 
Hypertriglyceridemia, with or without concomitant metabolic syndrome''.
    The invention pertains to compositions and methods of use of ApoC-
II mimetic peptides with multiple amphipathic alpha helical domains 
that have the dual ability to promote lipid efflux from cells and 
stimulate lipoprotein lipase activity, without inducing toxicity. This 
notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. 
The prospective Exclusive Patent License will be royalty bearing and 
may be granted unless within fifteen (15) days from the date of this 
published notice, the NHLBI Office of Technology Transfer and 
Development receives written evidence and argument that establishes 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are timely filed in response to this notice will be treated as 
objections to the grant

[[Page 16406]]

of the contemplated Exclusive Patent License. Comments and objections 
to this notice submitted will not be made available for public 
inspection and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: March 21, 2017.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager, Office of Technology Transfer 
and Development, National Heart, Lung, and Blood Institute.
[FR Doc. 2017-06546 Filed 4-3-17; 8:45 am]
 BILLING CODE 4140-01-P